Teva Pharmaceutical will reveal a restructuring plan on Thursday which includes shutting a research and development center.
The deal gives Arrakis rights to families of compounds that bind to three-way junctions found in folded RNA.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
The former CEO of Tennessee biotech Provectus treated the company as his “personal piggy bank,” taking millions from the business, says the SEC.
California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment.
The agreement will see Vernalis turn its fragment and structure-based drug discovery platform on undisclosed cancer targets.
Vertex and CRISPR will co-develop a beta-thalassemia and sickle cell treatment, the first to come out of their $105 million partnership.
PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment.
Just over a week ago, Spark Therapeutics was riding high on positive data for its hemophilia B gene therapy. It’s now fallen back to earth after spooking…
The bargain-basement takeout gives Allergan the rights to a troubled uterine fibroid drug that is on the cusp of phase 3.
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.